Recent trends in the synthesis of ‘Zolimidine’: a mini-review
Abstract Zolimidine, branded as ‘Solimidin’ is a gastroprotective drug based on imidazo[1,2-a] pyridine (imidazo[1,2-a]pyridine) nucleus. The limited synthetic protocols of zolimidine include C–S bond formation, C–N bond formation via C–H activation, S–O bond formation and subsequent derivatization, dehydrogenative heteroannulation, Ortoleva-King-type synthesis, dehydrogenative cyclocondensation, one-pot synthesis reactions, oxidative cross-coupling reactions, and oxidative cyclocondensation. In most of the cases for the synthesis of zolimidine, the formation of parent imidazo[1,2-a] pyridine ring occurs via (using) metal-based catalysts followed by its subsequent functionalization. The therapeutic efficacy of zolimidine as confirmed by its clinical evaluation makes it highly desirable to develop the drug analogs for the critical appraisal and improvement of drug pharmacokinetics and metabolism. In this review, we have discussed the various synthetic strategies aimed at the synthesis of zolimidine, and their chemistry thereof..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Chemical papers - 78(2023), 1 vom: 13. Okt., Seite 93-109 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Prasher, Parteek [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
]pyridine |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to the Institute of Chemistry, Slovak Academy of Sciences 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11696-023-03119-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054506999 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054506999 | ||
| 003 | DE-627 | ||
| 005 | 20240125064755.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11696-023-03119-1 |2 doi | |
| 035 | |a (DE-627)SPR054506999 | ||
| 035 | |a (SPR)s11696-023-03119-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Prasher, Parteek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent trends in the synthesis of ‘Zolimidine’: a mini-review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to the Institute of Chemistry, Slovak Academy of Sciences 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Zolimidine, branded as ‘Solimidin’ is a gastroprotective drug based on imidazo[1,2-a] pyridine (imidazo[1,2-a]pyridine) nucleus. The limited synthetic protocols of zolimidine include C–S bond formation, C–N bond formation via C–H activation, S–O bond formation and subsequent derivatization, dehydrogenative heteroannulation, Ortoleva-King-type synthesis, dehydrogenative cyclocondensation, one-pot synthesis reactions, oxidative cross-coupling reactions, and oxidative cyclocondensation. In most of the cases for the synthesis of zolimidine, the formation of parent imidazo[1,2-a] pyridine ring occurs via (using) metal-based catalysts followed by its subsequent functionalization. The therapeutic efficacy of zolimidine as confirmed by its clinical evaluation makes it highly desirable to develop the drug analogs for the critical appraisal and improvement of drug pharmacokinetics and metabolism. In this review, we have discussed the various synthetic strategies aimed at the synthesis of zolimidine, and their chemistry thereof. | ||
| 650 | 4 | |a Zolimidine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Imidazo[1,2- |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a ]pyridine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a C2-functionalization |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ortoleva-King type cyclization |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a 2-aminopyridine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Imine-enamine tautomerism |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Sharma, Mousmee |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemical papers |d Wien : Springer Vienna, 1947 |g 78(2023), 1 vom: 13. Okt., Seite 93-109 |w (DE-627)SPR021863229 |w (DE-600)2252770-9 |x 1336-9075 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:1 |g day:13 |g month:10 |g pages:93-109 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11696-023-03119-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 1 |b 13 |c 10 |h 93-109 | ||